LAKE FOREST, Calif. / Oct 30, 2024 / Business Wire / The end of the paragraph after bullets in the "Outlook" section of release should read: APAC sales growth of 5% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%) and all other APAC countries approximately 10-20% growth (prior outlook was flat). (Instead of: APAC sales growth of 4% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%).
The updated release reads:
STAAR SURGICAL REPORTS THIRD QUARTER 2024 RESULTS
Net Sales Up 10% to $88.6 Million Driven by Growth in All Regions
Americas Up 14%, EMEA Up 12% and APAC Up 9%
Market Building Initiatives Drive EVO ICL™ Uptake and Reinforce Opportunity
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the third quarter ended September 27, 2024.
Third Quarter 2024 Overview
“In the third quarter, we achieved double-digit sales growth against a macroeconomic environment that softened in the second half of the quarter, particularly in China,” said Tom Frinzi, President and CEO of STAAR Surgical. “STAAR is well positioned to navigate through the current market dynamics, which we believe are transitory. Looking ahead, we are encouraged by the recent shift in fiscal policy and announced stimulus in China and will continue to closely monitor the potential impact on our near to midterm growth outlook.”
Mr. Frinzi concluded, “Our focus on customer engagement and market expansion continues to yield solid results, helping drive industry-leading growth and market share gains. As our surgeon customers perform more EVO procedures, they are increasingly using our technology for moderate myopia, which underscores EVO ICL as the treatment choice for -6D and above and expands our total addressable market.”
Third Quarter 2024 Financial Results
Net sales were $88.6 million for the third quarter of 2024, up 10% from $80.3 million reported in the prior year quarter. This sales increase was driven by ICL sales growth of $8.0 million, up 10%, and unit growth of 6% from the prior year period. Other Product sales declined $0.2 million from the prior year period. Changes in currency, primarily the Japanese Yen, negatively impacted reported total net sales by $0.3 million for the third quarter of 2024.
Gross profit margin for the third quarter of 2024 was 77.3% of net sales as compared to the prior year quarter of 79.2% of net sales. Gross margin in the third quarter was lower primarily due to reduced unit production that resulted in less absorption of fixed overhead.
Operating expenses for the third quarter of 2024 were $62.8 million, up from the prior year quarter of $57.3 million. General and administrative expenses were $21.7 million, up from $19.3 million in the prior year quarter, driven primarily by increased facility costs and compensation-related expenses. Selling and marketing expenses were $26.6 million – consistent with the prior year quarter. Research and development expenses were $14.5 million, up from the prior year quarter of $11.5 million, primarily due to purchases of in-process research and development, as well as compensation-related expenses, which were partially offset by lower clinical trial costs.
Operating income for the third quarter of 2024 was $5.7 million or 6.4% of net sales as compared to operating income of $6.3 million or 7.8% of net sales for the third quarter of 2023.
Net income for the third quarter of 2024 was $10.0 million or $0.20 income per share, up from $4.8 million or $0.10 income per share for the prior year quarter. The increase in net income was primarily attributable to a gain on foreign currency transactions.
As of September 27, 2024, cash, cash equivalents and investments available for sale totaled $236.0 million, up from $232.4 million on December 29, 2023.
Outlook
The Company maintained its prior outlook for fiscal year 2024 net sales and Adjusted EBITDA.
The outlook above contemplates EVO ICL sales growth of 17% in the Americas (prior outlook was 15%) including 20% in the U.S. (prior outlook was 25%); EMEA sales growth of 10% (prior outlook was 6%); and APAC sales growth of 5% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%) and all other APAC countries approximately 10-20% growth (prior outlook was flat).
Earnings Webcast
The Company will host an earnings webcast today, Wednesday, October 30 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the webcast please use the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=fmU0YbKB.
The live webcast, earnings webcast presentation and an archived version of the webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.
Use of Non-GAAP Financial Measures
To supplement the Company’s financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), this press release and the accompanying tables include certain non-GAAP financial measures, including Adjusted EBITDA. Management uses these non-GAAP financial measures in its evaluation of Company operating performance and believes investors will find them useful in evaluating the Company’s operating performance, including cash flow generation, and in analyzing period-to-period financial performance of core business operations and underlying business trends. Non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.
EBITDA is a non-GAAP financial measure, which is calculated by adding interest income and expense, net; provision for income taxes; and depreciation and amortization to net income. In calculating Adjusted EBITDA and Adjusted EBITDA per diluted share, the Company further adjusts for stock-based compensation expense. As stock-based compensation is a non-cash expense that can vary significantly based on the timing, size and nature of awards granted, the Company believes that the exclusion of stock-based compensation expense can assist investors in comparisons of Company operating results with other peer companies because (i) the amount of such expense in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expense can vary significantly between periods as a result of the timing of grants of new stock-based awards, including inducement grants in connection with hiring. Additionally, the Company believes that excluding stock-based compensation from Adjusted EBITDA and Adjusted EBITDA per diluted share assists management and investors in making meaningful comparisons between the Company’s operating performance and the operating performance of other companies that may use different forms of employee compensation or different valuation methodologies for their stock-based compensation. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods. Investors should also note that such expenses will recur in the future.
The Company also presents certain financial information on a constant currency basis, which is intended to exclude the effects of foreign currency fluctuations. The Company conducts a significant part of its activities outside the U.S. It receives sales revenue and pays expenses principally in U.S. dollars, Swiss francs, Japanese yen and euros. The exchange rates between dollars and non-U.S. currencies can fluctuate greatly and can have a significant effect on the Company’s results when reported in U.S. dollars. In order to compare the Company's performance from period to period without the effect of currency, the Company will apply the same average exchange rate applicable in the prior period, or the “constant currency” rate to sales or expenses in the current period as well.
In the tables provided below, the Company has included a reconciliation of Adjusted EBITDA and Adjusted EBITDA per diluted share to net income and net income per diluted share, the most directly comparable GAAP financial measure, as well as supplemental financial information with net sales expressed in constant currency. The Company has also provided a reconciliation of forward-looking Adjusted EBITDA and Adjusted EBITDA per diluted share to net income and net income per diluted share. This represents forward-looking information, and actual results may vary. Please see the risks and assumptions referred to in the Safe Harbor section of this press release.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.
Safe Harbor
All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, anticipated financial results, estimates and outlook (including as to net sales, Adjusted EBITDA, and Adjusted EBITDA per diluted share), plans, strategies, and objectives of management for 2024 and beyond or prospects for achieving such plans, expectations for sales, revenue, margin, expenses or earnings, and any statements of assumptions underlying any of the foregoing, including those relating to financial performance in the upcoming quarter, fiscal year 2024 and beyond. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties related to global economic conditions, as well as the factors set forth in the Company’s Annual Report on Form 10-K for the year ended December 29, 2023 under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investor Information” section of the company’s website under the heading “SEC Filings.” We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the impact of COVID-19; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before or after approval, or to take enforcement action; international conflicts, trade disputes and substantial dependence on demand from Asia; and the willingness of surgeons and patients to adopt a new or improved product and procedure.
We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the ‘Investor Relations’ sections. Accordingly, investors should monitor such portions of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts.
| Consolidated Balance Sheets | ||||||||
| (in 000's) | ||||||||
| Unaudited | ||||||||
| ASSETS | September 27, 2024 | December 29, 2023 | ||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 164,003 |
| $ | 183,038 |
| ||
| Investments available for sale |
| 71,955 |
|
| 37,688 |
| ||
| Accounts receivable trade, net |
| 104,510 |
|
| 94,704 |
| ||
| Inventories, net |
| 40,361 |
|
| 35,130 |
| ||
| Prepayments, deposits, and other current assets |
| 16,277 |
|
| 14,709 |
| ||
| Total current assets |
| 397,106 |
|
| 365,269 |
| ||
| Investments available for sale |
| - |
|
| 11,703 |
| ||
| Property, plant, and equipment, net |
| 81,580 |
|
| 66,835 |
| ||
| Finance lease right-of-use assets, net |
| 73 |
|
| 183 |
| ||
| Operating lease right-of-use assets, net |
| 37,897 |
|
| 34,387 |
| ||
| Goodwill |
| 1,786 |
|
| 1,786 |
| ||
| Deferred income taxes |
| 5,324 |
|
| 5,190 |
| ||
| Other assets |
| 13,824 |
|
| 3,339 |
| ||
| Total assets | $ | 537,590 |
| $ | 488,692 |
| ||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 14,694 |
| $ | 13,557 |
| ||
| Obligations under finance leases |
| 84 |
|
| 165 |
| ||
| Obligations under operating leases |
| 4,531 |
|
| 4,202 |
| ||
| Allowance for sales returns |
| 8,124 |
|
| 6,174 |
| ||
| Other current liabilities |
| 38,908 |
|
| 40,938 |
| ||
| Total current liabilities |
| 66,341 |
|
| 65,036 |
| ||
| Obligations under finance leases |
| - |
|
| 42 |
| ||
| Obligations under operating leases |
| 35,385 |
|
| 31,425 |
| ||
| Deferred income taxes |
| 1,056 |
|
| 1,077 |
| ||
| Asset retirement obligations |
| 127 |
|
| 103 |
| ||
| Pension liability |
| 6,559 |
|
| 5,055 |
| ||
| Total liabilities |
| 109,468 |
|
| 102,738 |
| ||
| Stockholders' equity: | ||||||||
| Common stock |
| 493 |
|
| 488 |
| ||
| Additional paid-in capital |
| 466,579 |
|
| 436,947 |
| ||
| Accumulated other comprehensive loss |
| (5,602 | ) |
| (4,113 | ) | ||
| Accumulated deficit |
| (33,348 | ) |
| (47,368 | ) | ||
| Total stockholders' equity |
| 428,122 |
|
| 385,954 |
| ||
| Total liabilities and stockholders' equity | $ | 537,590 |
| $ | 488,692 |
| ||
| Consolidated Statements of Income | ||||||||||||||||||||||||||||||||||||
| (in 000's except for per share data) | ||||||||||||||||||||||||||||||||||||
| Unaudited | ||||||||||||||||||||||||||||||||||||
| Three Months Ended | Year to Date | |||||||||||||||||||||||||||||||||||
% of Sales |
| September 27, 2024 |
| % of Sales |
| September 29, 2023 |
| Fav (Unfav) Amount |
| % |
| % of Sales |
| September 27, 2024 |
| % of Sales |
| September 29, 2023 |
| Fav (Unfav) Amount |
| % | ||||||||||||||
| Net sales | 100.0% | $ | 88,590 | 100.0% | $ | 80,308 |
| $ | 8,282 |
| 10.3% | 100.0% | $ | 264,951 | 100.0% | $ | 246,142 |
| $ | 18,809 |
| 7.6% | ||||||||||||||
| Cost of sales | 22.7% |
| 20,103 |
| 20.8% |
| 16,670 |
|
| (3,433 | ) | (20.6)% | 21.5% |
| 57,017 |
| 22.0% |
| 54,216 |
|
| (2,801 | ) | (5.2)% | ||||||||||||
| Gross profit | 77.3% |
| 68,487 |
| 79.2% |
| 63,638 |
|
| 4,849 |
| 7.6% | 78.5% |
| 207,934 |
| 78.0% |
| 191,926 |
|
| 16,008 |
| 8.3% | ||||||||||||
| Selling, general and administrative expenses: | ||||||||||||||||||||||||||||||||||||
| General and administrative | 24.4% |
| 21,685 |
| 24.0% |
| 19,266 |
|
| (2,419 | ) | (12.6)% | 25.9% |
| 68,554 |
| 22.6% |
| 55,461 |
|
| (13,093 | ) | (23.6)% | ||||||||||||
| Selling and marketing | 30.1% |
| 26,623 |
| 33.1% |
| 26,607 |
|
| (16 | ) | (0.1)% | 31.0% |
| 82,150 |
| 34.6% |
| 85,238 |
|
| 3,088 |
| 3.6% | ||||||||||||
| Research and development | 16.4% |
| 14,497 |
| 14.3% |
| 11,470 |
|
| (3,027 | ) | (26.4)% | 15.8% |
| 41,931 |
| 13.6% |
| 33,535 |
|
| (8,396 | ) | (25.0)% | ||||||||||||
| Total selling, general, and administrative expenses | 70.9% |
| 62,805 |
| 71.4% |
| 57,343 |
|
| (5,462 | ) | (9.5)% | 72.7% |
| 192,635 |
| 70.8% |
| 174,234 |
|
| (18,401 | ) | (10.6)% | ||||||||||||
| Operating income | 6.4% |
| 5,682 |
| 7.8% |
| 6,295 |
|
| (613 | ) | (9.7)% | 5.8% |
| 15,299 |
| 7.2% |
| 17,692 |
|
| (2,393 | ) | (13.5)% | ||||||||||||
| Other income (expense): | ||||||||||||||||||||||||||||||||||||
| Interest income, net | 1.6% |
| 1,407 |
| 2.1% |
| 1,690 |
|
| (283 | ) | (16.7)% | 1.6% |
| 4,358 |
| 2.1% |
| 5,287 |
|
| (929 | ) | (17.6)% | ||||||||||||
| Gain (loss) on foreign currency transactions | 6.7% |
| 5,931 |
| -1.7% |
| (1,384 | ) |
| 7,315 |
| 528.5% | 0.2% |
| 585 |
| -1.3% |
| (3,240 | ) |
| 3,825 |
| 118.1% | ||||||||||||
| Royalty income | 0.0% |
| - |
| 0.1% |
| 74 |
|
| (74 | ) | (100.0)% | 0.2% |
| 508 |
| 0.0% |
| 74 |
|
| 434 |
| 586.5% | ||||||||||||
| Other income, net | 0.2% |
| 139 |
| 0.1% |
| 71 |
|
| 68 |
| 95.8% | 0.2% |
| 532 |
| 0.1% |
| 144 |
|
| 388 |
| 269.4% | ||||||||||||
| Total other income, net | 8.5% |
| 7,477 |
| 0.6% |
| 451 |
|
| 7,026 |
| 1557.9% | 2.2% |
| 5,983 |
| 0.9% |
| 2,265 |
|
| 3,718 |
| 164.2% | ||||||||||||
| Income before provision for income taxes | 14.9% |
| 13,159 |
| 8.4% |
| 6,746 |
|
| 6,413 |
| 95.1% | 8.0% |
| 21,282 |
| 8.1% |
| 19,957 |
|
| 1,325 |
| 6.6% | ||||||||||||
| Provision for income taxes | 3.6% |
| 3,179 |
| 2.4% |
| 1,929 |
|
| (1,250 | ) | (64.8)% | 2.7% |
| 7,262 |
| 2.6% |
| 6,366 |
|
| (896 | ) | (14.1)% | ||||||||||||
| Net income | 11.3% |
| 9,980 |
| 6.0% |
| 4,817 |
|
| 5,163 |
| 107.2% | 5.3% |
| 14,020 |
| 5.5% |
| 13,591 |
|
| 429 |
| 3.2% | ||||||||||||
| Net income per share - basic |
| 0.20 |
|
| 0.10 |
|
| 0.29 |
|
| 0.28 |
| ||||||||||||||||||||||||
| Net income per share - diluted |
| 0.20 |
|
| 0.10 |
|
| 0.28 |
|
| 0.27 |
| ||||||||||||||||||||||||
| Weighted average shares outstanding - basic |
| 49,199 |
|
| 48,613 |
|
| 49,078 |
|
| 48,426 |
| ||||||||||||||||||||||||
| Weighted average shares outstanding - diluted |
| 49,731 |
|
| 49,370 |
|
| 49,614 |
|
| 49,494 |
| ||||||||||||||||||||||||
| Consolidated Statements of Cash Flows | ||||||||||||||||
| (in 000's) | ||||||||||||||||
| Unaudited | ||||||||||||||||
| Three Months Ended | Year to Date | |||||||||||||||
September 27, 2024 | September 29, 2023 | September 27, 2024 | September 29, 2023 | |||||||||||||
| Cash flows from operating activities: | ||||||||||||||||
| Net income | $ | 9,980 |
| $ | 4,817 |
| $ | 14,020 |
| $ | 13,591 |
| ||||
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | ||||||||||||||||
| Depreciation of property and equipment |
| 1,757 |
|
| 1,345 |
|
| 4,516 |
|
| 3,743 |
| ||||
| Amortization of long-lived intangibles |
| - |
|
| (2 | ) |
| - |
|
| 169 |
| ||||
| Accretion/Amortization of investments available for sale |
| (124 | ) |
| (348 | ) |
| (410 | ) |
| (2,172 | ) | ||||
| Deferred income taxes |
| (13 | ) |
| (10 | ) |
| 47 |
|
| 65 |
| ||||
| Change in net pension liability |
| (16 | ) |
| (139 | ) |
| (162 | ) |
| (766 | ) | ||||
| Stock-based compensation expense |
| 7,160 |
|
| 8,846 |
|
| 22,541 |
|
| 23,334 |
| ||||
| Change in asset retirement obligation |
| 4 |
|
| 3 |
|
| 24 |
|
| (104 | ) | ||||
| Loss on disposal of property and equipment |
| 1,642 |
|
| 17 |
|
| 1,668 |
|
| 41 |
| ||||
| Provision for sales returns and bad debts |
| 868 |
|
| 921 |
|
| 1,947 |
|
| 1,925 |
| ||||
| Inventory provision |
| 849 |
|
| 460 |
|
| 1,873 |
|
| 4,090 |
| ||||
| Changes in working capital: | ||||||||||||||||
| Accounts receivable |
| (10,139 | ) |
| (18,092 | ) |
| (9,703 | ) |
| (50,436 | ) | ||||
| Inventories |
| (1,091 | ) |
| (5,593 | ) |
| (5,962 | ) |
| (9,975 | ) | ||||
| Prepayments, deposits and other assets |
| (5,152 | ) |
| (919 | ) |
| (12,237 | ) |
| (3,584 | ) | ||||
| Accounts payable |
| (5,649 | ) |
| (1,819 | ) |
| (2,031 | ) |
| (3,266 | ) | ||||
| Other current liabilities |
| 3,740 |
|
| 4,538 |
|
| (1,048 | ) |
| 5,970 |
| ||||
| Net cash provided by (used in) operating activities |
| 3,816 |
|
| (5,975 | ) |
| 15,083 |
|
| (17,375 | ) | ||||
| Cash flows from investing activities: | ||||||||||||||||
| Acquisition of property and equipment |
| (6,231 | ) |
| (9,185 | ) |
| (17,669 | ) |
| (15,100 | ) | ||||
| Purchase of investments available for sale |
| (40,945 | ) |
| (9,712 | ) |
| (61,194 | ) |
| (52,314 | ) | ||||
| Proceeds from sale or maturity of investments available for sale |
| 11,935 |
|
| 50,737 |
|
| 39,141 |
|
| 119,359 |
| ||||
| Net provided by (used in) investing activities |
| (35,241 | ) |
| 31,840 |
|
| (39,722 | ) |
| 51,945 |
| ||||
| Cash flows from financing activities: | ||||||||||||||||
| Repayment of finance lease obligations |
| (42 | ) |
| (39 | ) |
| (124 | ) |
| (121 | ) | ||||
| Repurchase of employee common stock for taxes withheld |
| - |
|
| (112 | ) |
| (1,396 | ) |
| (2,096 | ) | ||||
| Proceeds from vested restricted stock and exercise of stock options |
| 1,657 |
|
| 7,258 |
|
| 7,354 |
|
| 9,265 |
| ||||
| Net cash provided by financing activities |
| 1,615 |
|
| 7,107 |
|
| 5,834 |
|
| 7,048 |
| ||||
| Effect of exchange rate changes on cash and cash equivalents |
| 1,037 |
|
| (235 | ) |
| (230 | ) |
| (666 | ) | ||||
| Increase (decrease) in cash and cash equivalents |
| (28,773 | ) |
| 32,737 |
|
| (19,035 | ) |
| 40,952 |
| ||||
| Cash and cash equivalents, at beginning of the period |
| 192,776 |
|
| 94,695 |
|
| 183,038 |
|
| 86,480 |
| ||||
| Cash and cash equivalents, at end of the period | $ | 164,003 |
| $ | 127,432 |
| $ | 164,003 |
| $ | 127,432 |
| ||||
| Reconciliation of Non-GAAP Financial Measure | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net Income to Adjusted EBITDA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (in 000's except for per share data) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Unaudited | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2021 |
| Q1-22 |
| Q2-22 |
| Q3-22 |
| Q4-22 |
| 2022 |
| Q1-23 |
| Q2-23 |
| Q3-23 |
| Q4-23 |
| 2023 |
| Q1-24 |
| Q2-24 |
| Q3-24 |
| 2024 Outlook(2) | ||||||||||||||||||||||||||||||||
| Net income (loss) - (as reported) | $ | 27,511 |
| $ | 9,602 |
| $ | 13,038 |
| $ | 10,262 |
| $ | 6,763 |
| $ | 39,665 |
| $ | 2,710 |
| $ | 6,064 |
| $ | 4,817 |
| $ | 7,756 |
| $ | 21,347 |
| $ | (3,339 | ) | $ | 7,379 |
| $ | 9,980 |
| $ | 3,800 |
| |||||||||||||||
| Provision (benefit) for income taxes |
| 3,793 |
|
| 1,925 |
|
| 2,431 |
|
| 2,315 |
|
| (784 | ) |
| 5,887 |
|
| 2,009 |
|
| 2,428 |
|
| 1,929 |
|
| 5,983 |
|
| 12,349 |
|
| 1,128 |
|
| 2,955 |
|
| 3,179 |
|
| 7,600 |
| |||||||||||||||
| Other (income) expense, net |
| 2,035 |
|
| 586 |
|
| 1,551 |
|
| 1,128 |
|
| (5,015 | ) |
| (1,750 | ) |
| (1,919 | ) |
| 105 |
|
| (451 | ) |
| (3,334 | ) |
| (5,599 | ) |
| (70 | ) |
| 1,564 |
|
| (7,477 | ) |
| (7,500 | ) | |||||||||||||||
| Depreciation |
| 3,608 |
|
| 994 |
|
| 1,030 |
|
| 1,077 |
|
| 1,380 |
|
| 4,481 |
|
| 1,113 |
|
| 1,285 |
|
| 1,345 |
|
| 1,368 |
|
| 5,111 |
|
| 1,237 |
|
| 1,522 |
|
| 1,757 |
|
| 6,000 |
| |||||||||||||||
| (Gain) loss on disposal of property plant and equipment(3) |
| 2 |
|
| - |
|
| - |
|
| - |
|
| 65 |
|
| 65 |
|
| - |
|
| 24 |
|
| 17 |
|
| 32 |
|
| 73 |
|
| - |
|
| 26 |
|
| 1,642 |
|
| 1,700 |
| |||||||||||||||
| Amortization of intangible assets |
| 34 |
|
| 8 |
|
| 7 |
|
| 7 |
|
| 6 |
|
| 28 |
|
| 7 |
|
| 10 |
|
| (2 | ) |
| (2 | ) |
| 13 |
|
| - |
|
| - |
|
| - |
|
| - |
| |||||||||||||||
| Stock-based compensation |
| 14,605 |
|
| 3,894 |
|
| 5,754 |
|
| 5,727 |
|
| 4,996 |
|
| 20,371 |
|
| 6,065 |
|
| 8,423 |
|
| 8,846 |
|
| 182 |
|
| 23,516 |
|
| 6,339 |
|
| 9,042 |
|
| 7,160 |
|
| 30,200 |
| |||||||||||||||
| Adjusted EBITDA | $ | 51,588 |
| $ | 17,009 |
| $ | 23,811 |
| $ | 20,516 |
| $ | 7,411 |
| $ | 68,747 |
| $ | 9,985 |
| $ | 18,339 |
| $ | 16,501 |
| $ | 11,985 |
| $ | 56,810 |
| $ | 5,295 |
| $ | 22,488 |
| $ | 16,241 |
| $ | 41,800 |
| |||||||||||||||
| Adjusted EBITDA as a % of Revenue |
| 22.4 | % |
| 26.9 | % |
| 29.4 | % |
| 27.0 | % |
| 11.6 | % |
| 24.2 | % |
| 13.6 | % |
| 19.9 | % |
| 20.6 | % |
| 15.7 | % |
| 17.6 | % |
| 6.8 | % |
| 22.7 | % |
| 18.3 | % |
| 12.2 | % | |||||||||||||||
| Net income (loss) per share, diluted - (as reported) | $ | 0.56 |
| $ | 0.19 |
| $ | 0.26 |
| $ | 0.21 |
| $ | 0.14 |
| $ | 0.80 |
| $ | 0.05 |
| $ | 0.12 |
| $ | 0.10 |
| $ | 0.16 |
| $ | 0.43 |
| $ | (0.07 | ) | $ | 0.15 |
| $ | 0.20 |
| $ | 0.07 |
| |||||||||||||||
| Provision (benefit) for income taxes |
| 0.08 |
|
| 0.04 |
|
| 0.05 |
|
| 0.05 |
|
| (0.02 | ) |
| 0.12 |
|
| 0.04 |
|
| 0.05 |
|
| 0.04 |
|
| 0.12 |
|
| 0.25 |
|
| 0.02 |
|
| 0.06 |
|
| 0.06 |
|
| 0.15 |
| |||||||||||||||
| Other (income) expense, net |
| 0.04 |
|
| 0.01 |
|
| 0.03 |
|
| 0.02 |
|
| (0.10 | ) |
| (0.04 | ) |
| (0.04 | ) |
| - |
|
| (0.01 | ) |
| (0.07 | ) |
| (0.11 | ) |
| - |
|
| 0.03 |
|
| (0.15 | ) |
| (0.14 | ) | |||||||||||||||
| Depreciation |
| 0.07 |
|
| 0.02 |
|
| 0.02 |
|
| 0.02 |
|
| 0.03 |
|
| 0.09 |
|
| 0.02 |
|
| 0.03 |
|
| 0.03 |
|
| 0.03 |
|
| 0.10 |
|
| 0.03 |
|
| 0.03 |
|
| 0.04 |
|
| 0.12 |
| |||||||||||||||
| (Gain) loss on disposal of property plant and equipment |
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| 0.03 |
|
| 0.03 |
| |||||||||||||||
| Amortization of intangible assets |
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| - |
|
| - |
| |||||||||||||||
| Stock-based compensation |
| 0.30 |
|
| 0.08 |
|
| 0.12 |
|
| 0.12 |
|
| 0.10 |
|
| 0.41 |
|
| 0.12 |
|
| 0.17 |
|
| 0.18 |
|
| - |
|
| 0.48 |
|
| 0.13 |
|
| 0.18 |
|
| 0.14 |
|
| 0.58 |
| |||||||||||||||
| Adjusted EBITDA per share, diluted(1) | $ | 1.04 |
| $ | 0.35 |
| $ | 0.48 |
| $ | 0.41 |
| $ | 0.15 |
| $ | 1.39 |
| $ | 0.20 |
| $ | 0.37 |
| $ | 0.33 |
| $ | 0.24 |
| $ | 1.15 |
| $ | 0.11 |
| $ | 0.45 |
| $ | 0.33 |
| $ | 0.80 |
| |||||||||||||||
| Weighted average shares outstanding - Diluted |
| 49,456 |
|
| 49,288 |
|
| 49,223 |
|
| 49,549 |
|
| 49,389 |
|
| 49,380 |
|
| 49,500 |
|
| 49,516 |
|
| 49,370 |
|
| 49,242 |
|
| 49,427 |
|
| 48,907 |
|
| 49,811 |
|
| 49,731 |
|
| 52,000 |
| |||||||||||||||
| (1) Adjusted EBITDA per diluted share may not add due to rounding | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (2) 2024 Adjusted EBITDA Outlook line items are all approximations and assumes breakeven Net Income | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (3) The Q3-2024 non cash write-off of $1.6M was related to the former EVO Experience Center | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ICL Sales by Geography | ||||||||||||||||||||||||||||||||||||
| (in 000's) | ||||||||||||||||||||||||||||||||||||
| Unaudited | ||||||||||||||||||||||||||||||||||||
| Fiscal Year | Three Months Ended | |||||||||||||||||||||||||||||||||||
| ICL Sales by Region(5) | 2021 | 2022 | 2023 | June 30, 2023 | September 29, 2023 | December 29, 2023 | March 29, 2024 | June 28, 2024 | September 27, 2024 | |||||||||||||||||||||||||||
| Americas(1) | $ | 14,054 |
| $ | 20,114 |
| $ | 22,233 |
| $ | 5,954 |
| $ | 5,449 |
| $ | 5,264 |
| $ | 6,260 |
| $ | 6,794 |
| $ | 6,187 |
| |||||||||
| EMEA(2) |
| 37,343 |
|
| 36,715 |
|
| 39,318 |
|
| 9,782 |
|
| 9,253 |
|
| 10,103 |
|
| 11,299 |
|
| 10,727 |
|
| 10,333 |
| |||||||||
| APAC(3) |
| 161,508 |
|
| 212,883 |
|
| 257,876 |
|
| 77,376 |
|
| 66,367 |
|
| 59,254 |
|
| 59,592 |
|
| 81,844 |
|
| 72,581 |
| |||||||||
| Global ICL Sales | $ | 212,905 |
| $ | 269,712 |
| $ | 319,427 |
| $ | 93,112 |
| $ | 81,069 |
| $ | 74,621 |
| $ | 77,151 |
| $ | 99,365 |
| $ | 89,101 |
| |||||||||
| Global ICL Sales Growth |
| 51 | % |
| 27 | % |
| 18 | % |
| 19 | % |
| 13 | % |
| 22 | % |
| 9 | % |
| 7 | % |
| 10 | % | |||||||||
| Americas ICL Sales Growth |
| 59 | % |
| 43 | % |
| 11 | % |
| 12 | % |
| 5 | % |
| (8 | )% |
| 12 | % |
| 14 | % |
| 14 | % | |||||||||
| EMEA ICL Sales Growth |
| 45 | % |
| (2 | )% |
| 7 | % |
| (11 | )% |
| 14 | % |
| 18 | % |
| 11 | % |
| 10 | % |
| 12 | % | |||||||||
| APAC ICL Sales Growth |
| 51 | % |
| 32 | % |
| 21 | % |
| 26 | % |
| 13 | % |
| 26 | % |
| 9 | % |
| 6 | % |
| 9 | % | |||||||||
| Global ICL Unit Growth |
| 48 | % |
| 33 | % |
| 19 | % |
| 21 | % |
| 14 | % |
| 19 | % |
| 2 | % |
| 3 | % |
| 6 | % | |||||||||
| Fiscal Year | Three Months Ended | |||||||||||||||||||||||||||||||||||
| ICL Sales by Country(4)(5) | 2021 | 2022 | 2023 | June 30, 2023 | September 29, 2023 | December 29, 2023 | March 29, 2024 | June 28, 2024 | September 27, 2024 | |||||||||||||||||||||||||||
| China | $ | 107,130 |
| $ | 147,967 |
| $ | 185,404 |
| $ | 61,288 |
| $ | 48,262 |
| $ | 40,813 |
| $ | 38,460 |
| $ | 63,345 |
| $ | 51,719 |
| |||||||||
| Growth |
| 50 | % |
| 38 | % |
| 25 | % |
| 33 | % |
| 14 | % |
| 30 | % |
| 10 | % |
| 3 | % |
| 7 | % | |||||||||
| Japan | $ | 28,688 |
| $ | 32,623 |
| $ | 36,352 |
| $ | 8,563 |
| $ | 9,091 |
| $ | 9,495 |
| $ | 10,227 |
| $ | 9,735 |
| $ | 10,490 |
| |||||||||
| Growth |
| 56 | % |
| 14 | % |
| 11 | % |
| 13 | % |
| 12 | % |
| 16 | % |
| 11 | % |
| 14 | % |
| 15 | % | |||||||||
| South Korea | $ | 15,173 |
| $ | 17,940 |
| $ | 19,853 |
| $ | 3,316 |
| $ | 4,886 |
| $ | 4,996 |
| $ | 6,725 |
| $ | 3,973 |
| $ | 5,434 |
| |||||||||
| Growth |
| 36 | % |
| 18 | % |
| 11 | % |
| (15 | )% |
| 1 | % |
| 39 | % |
| 1 | % |
| 20 | % |
| 11 | % | |||||||||
| United States | $ | 9,478 |
| $ | 15,070 |
| $ | 17,168 |
| $ | 4,446 |
| $ | 4,162 |
| $ | 4,164 |
| $ | 5,039 |
| $ | 5,541 |
| $ | 4,823 |
| |||||||||
| Growth |
| 58 | % |
| 59 | % |
| 14 | % |
| 10 | % |
| 6 | % |
| (8 | )% |
| 15 | % |
| 25 | % |
| 16 | % | |||||||||
| Notes: | ||||||||||||||||||||||||||||||||||||
| (1) Americas includes the United States, Canada and Latin American countries | ||||||||||||||||||||||||||||||||||||
| (2) EMEA includes Spain, Germany, United Kingdom, European, Middle East and Africa Distributors | ||||||||||||||||||||||||||||||||||||
| (3) APAC includes China, Japan, South Korea, India and the rest of Asia Pacific distributors | ||||||||||||||||||||||||||||||||||||
| (4) ICL Sales by country includes countries representing more than 5% of total ICL sales in the most recently completed fiscal year | ||||||||||||||||||||||||||||||||||||
| (5) ICL sales do not include IOL, injector or other sales | ||||||||||||||||||||||||||||||||||||
| Reconciliation of Non-GAAP Financial Measure | ||||||||||||||||||||||||||||||
| Constant Currency Sales | ||||||||||||||||||||||||||||||
| (in 000's) | ||||||||||||||||||||||||||||||
| Unaudited | ||||||||||||||||||||||||||||||
| Three Months Ended | As Reported | Constant Currency | ||||||||||||||||||||||||||||
| Sales | September 27, 2024 | Effect of Currency | Constant Currency | September 29, 2023 | $ Change | % Change | $ Change | % Change | ||||||||||||||||||||||
| ICL | $ | 89,101 |
| $ | 300 |
| $ | 89,401 |
| $ | 81,069 |
| $ | 8,032 |
| 9.9 | % | $ | 8,332 |
| 10.3 | % | ||||||||
| Cataract IOL |
| - |
|
| - |
|
| - |
|
| (221 | ) |
| 221 |
| (100.0 | )% |
| 221 |
| (100.0 | )% | ||||||||
| Other |
| (511 | ) |
| (2 | ) |
| (513 | ) |
| (540 | ) |
| 29 |
| (5.4 | )% |
| 27 |
| (5.0 | )% | ||||||||
| Total Sales | $ | 88,590 |
| $ | 298 |
| $ | 88,888 |
| $ | 80,308 |
| $ | 8,282 |
| 10.3 | % | $ | 8,580 |
| 10.7 | % | ||||||||
| Year to Date | As Reported | Constant Currency | ||||||||||||||||||||||||||||
| Sales | September 27, 2024 | Effect of Currency | Constant Currency | September 29, 2023 | $ Change | % Change | $ Change | % Change | ||||||||||||||||||||||
| ICL | $ | 265,617 |
| $ | 2,515 |
| $ | 268,132 |
| $ | 244,806 |
| $ | 20,811 |
| 8.5 | % | $ | 23,326 |
| 9.5 | % | ||||||||
| Cataract IOL |
| - |
|
| - |
|
| - |
|
| 1,295 |
|
| (1,295 | ) | (100.0 | )% |
| (1,295 | ) | (100.0 | )% | ||||||||
| Other |
| (666 | ) |
| 111 |
|
| (555 | ) |
| 41 |
|
| (707 | ) | (1724.4 | )% |
| (596 | ) | (1453.7 | )% | ||||||||
| Total Sales | $ | 264,951 |
| $ | 2,626 |
| $ | 267,577 |
| $ | 246,142 |
| $ | 18,809 |
| 7.6 | % | $ | 21,435 |
| 8.7 | % | ||||||||
| Last Trade: | US$24.82 |
| Daily Change: | -0.16 -0.64 |
| Daily Volume: | 962,549 |
| Market Cap: | US$1.220B |
October 30, 2024 August 07, 2024 May 07, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
